Obefazimod: meta-analysis of COVID-19 studies

All studies   Mortality   Ventilation   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 305 patientsc19early.org

Obefazimod for COVID-19

Serious outcome risk
Obefazimod
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−101%
Mortality (1)−101%
Ventilation (1)−26%
RCTs (1)−101%
Late (1)−101%
00.511.5+
← Obefazimod
reduces riskIncreased
risk →
c19early.org
October 2026

Obefazimod COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Giavina-.. (DB RCT)−101%2.01 · 0.23–17.75death4/2031/102miR-AGE
Late treatment−101%2.01 · 0.23–17.754/2031/102101% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.54
All studies−101%2.01 · 0.23–17.754/2031/102101% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5400.511.52+
Rotate screen for more detailsIncrease width for more details
← Obefazimod
reduces riskObefazimod
increases risk →
c19early.org
October 2026

Obefazimod COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Giavina-.. (DB RCT)−101%2.01 · 0.23–17.754/2031/102miR-AGE
Late treatment−101%2.01 · 0.23–17.754/2031/102101% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.54
All studies−101%2.01 · 0.23–17.754/2031/102101% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5400.511.52+
Rotate screen for more detailsIncrease width for more details
← Obefazimod
reduces riskObefazimod
increases risk →
c19early.org
October 2026

Obefazimod COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Giavina-.. (DB RCT)−26%1.26 · 0.50–3.1415/2036/102miR-AGE
Late treatment−26%1.26 · 0.50–3.1415/2036/10226% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.64
All studies−26%1.26 · 0.50–3.1415/2036/10226% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+
Rotate screen for more detailsIncrease width for more details
← Obefazimod
reduces riskObefazimod
increases risk →
c19early.org
October 2026

Obefazimod COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Giavina-.. (DB RCT)−101%2.01 · 0.23–17.75death4/2031/102miR-AGE
Late treatment−101%2.01 · 0.23–17.754/2031/102101% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.54
All studies−101%2.01 · 0.23–17.754/2031/102101% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5400.511.52+
Rotate screen for more detailsIncrease width for more details
← Obefazimod
reduces riskObefazimod
increases risk →
c19early.org
October 2026

Obefazimod COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Giavina-.. (DB RCT)−101%2.01 · 0.23–17.75death4/2031/102miR-AGE
Late treatment−101%2.01 · 0.23–17.754/2031/102101% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.54
All studies−101%2.01 · 0.23–17.754/2031/102101% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5400.511.52+
Rotate screen for more detailsIncrease width for more details
← Obefazimod
reduces riskObefazimod
increases risk →
c19early.org
October 2026

Obefazimod COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Giavina-.. (DB RCT)−101%2.01 · 0.23–17.754/2031/102miR-AGE
Late treatment−101%2.01 · 0.23–17.754/2031/102101% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.54
All studies−101%2.01 · 0.23–17.754/2031/102101% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5400.511.52+
Rotate screen for more detailsIncrease width for more details
← Obefazimod
reduces riskObefazimod
increases risk →
c19early.org
October 2026

Obefazimod COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Giavina-.. (DB RCT)−101%2.01 · 0.23–17.75death4/2031/102miR-AGE
Late treatment−101%2.01 · 0.23–17.754/2031/102101% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.54
All studies−101%2.01 · 0.23–17.754/2031/102101% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5400.511.52+
Rotate screen for more detailsIncrease width for more details
← Obefazimod
reduces riskObefazimod
increases risk →